−23.6
Lineage Cell Therapeutics, Inc.
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25
(positive)
Change from FY21 to FY25
millions USD
FY21:
FY22:
1.06
FY23:
−28.6
FY24:
−23.1
FY25:
−18.9
Change from FY21 to FY25
millions USD
FY21:
9.75
FY22:
−46.2
FY23:
46.4
FY24:
−2.31
FY25:
−13.5
Change from FY21 to FY25
millions USD
FY21:
36.9
FY22:
1.63
FY23:
6.42
FY24:
35.9
FY25:
27.0
millions USD
FY21:
23.1
FY22:
−44.3
FY23:
24.1
FY24:
10.4
FY25:
−5.03
(positive)
Change from FY21 to FY25
millions USD
FY21:
−23.9
FY22:
0.65
FY23:
−29.2
FY24:
−23.7
FY25:
−19.4
All amounts in millions USD